McKesson Q1 Earnings Call Highlights

• 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles

McKesson (NYSE:MCK) reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum crossed its operating businesses and prompting the healthcare services institution to rise its full-year adjusted net outlook.

Revenue roseate 8% to $105.4 billion, portion adjusted diluted net per stock accrued 20% to $9.93. Chair and CEO Brian Tyler said 3 reporting segments posted double-digit operating-profit growth, supported by unchangeable utilization, measurement maturation and the company's portfolio of healthcare distribution, specialty and exertion services.

→ Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling

• MarketBeat Week successful Review – 07/27- 07/31

"Our archetypal 4th show reflects the continued momentum crossed the endeavor and reinforces our assurance successful our strategy and the durability of our operating model," Tyler said.

Guidance raised arsenic North American Pharmaceutical leads maturation

McKesson raised its fiscal 2027 adjusted EPS outlook to a scope of $44.20 to $45.00, from anterior guidance of $43.80 to $44.60. The revised outlook implies adjusted EPS maturation of 13% to 15%, excluding the interaction of the Norway divestiture and a fiscal 2026 summation tied to the merchantability of an equity concern wrong The US Oncology Network.

→ 4 Oil and Gas ETF Plays arsenic Prices Stay Sky-High

• McKesson's Compounding Keeps Adding Up

The institution expects fiscal-year gross maturation of 5% to 9% and operating-profit maturation of 9% to 13%.

North American Pharmaceutical gross accrued 5% to $86.8 billion. The segment's operating nett roseate 19% to $894 million, driven by specialty organisation growth, including wellness systems and strategical accounts, arsenic good arsenic the timing of caller merchandise launches.